卓勝微(300782.SZ):預計未來兩至三年內研發人員規模不會有大幅度的增長
格隆匯5月6日丨卓勝微(300782.SZ)於2023年4月28日接受機構調研,在問答環節中,就“未來研發人員是什麼樣的規劃佈局?”,公司回覆稱,截至到2022年年底公司研發人員快速增長,從上年同期的457人增長至838人,同比增長83.37%。公司已逐步建立了成熟的射頻器件及模組研發設計和工藝團隊,預計未來兩至三年內研發人員規模不會有大幅度的增長。公司新增的研發人員主要為滿足芯卓工藝產線的需求,主要為工藝工程師、設備工程師和材料工程師等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.